Compare ADTN & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ADTN | CERS |
|---|---|---|
| Founded | 1985 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | EDP Services |
| Sector | Telecommunications | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 684.4M | 585.1M |
| IPO Year | 1996 | 1996 |
| Metric | ADTN | CERS |
|---|---|---|
| Price | $7.27 | $2.54 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $15.50 | N/A |
| AVG Volume (30 Days) | 1.8M | ★ 2.1M |
| Earning Date | 05-04-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.83 | 27.27 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,083,807,000.00 | $51,326,000.00 |
| Revenue This Year | $11.09 | $19.95 |
| Revenue Next Year | $8.47 | $8.84 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 17.46 | ★ 30.68 |
| 52 Week Low | $7.11 | $1.17 |
| 52 Week High | $19.98 | $3.47 |
| Indicator | ADTN | CERS |
|---|---|---|
| Relative Strength Index (RSI) | 33.24 | 45.88 |
| Support Level | $7.43 | $2.37 |
| Resistance Level | $8.81 | $2.68 |
| Average True Range (ATR) | 0.29 | 0.11 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 5.01 | 15.53 |
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.